Significant progresses have been made in the inorganic and organic chemistry up to the present concerning the synthesis, characterization, and application of the metal complexes of pharmaceutical substances. From the wide range of fields in which these coordination compounds find their application, many efforts were focused on the study of their importance in the biological processes. The coordination complexes of many pharmaceutical substances having different pharmacological effects e.g., pyrazinamide (PZA), nicotinamide (NAM), nicotinic acid (NIC), theophylline (TEO), captopril (CPL), tolbutamide (TBA), clonidine (CLN), guanfacine (GUAF), etc. with transition metals were synthesized and used in order to improve their pharmacological and pharmacotechnical properties and also for the drug analysis and control. Several techniques such as Fourier transform infrared spectroscopy (FTIR), Raman spectroscopy, surface-enhanced Raman spectroscopy (SERS), X-ray spectroscopy, mass spectrometry, ultraviolet-visible (UV-Vis) spectrophotometry, electron paramagnetic resonance (EPR) spectroscopy, X-ray diffraction, elemental analysis, electrochemical methods, thermal methods, and scanning electron microscopy were used for the physicochemical characterization of the complex composition. A significant interest in the development of metal complex-based drugs with unique research and therapeutic and diagnostic opportunities is currently observed in the medicinal inorganic chemistry area.
- coordination complexes
- transition metals
- pharmaceutical substances
- characterization methods
- medicinal chemistry
The coordination complexes have been studied since 1798 starting with the Tassaert studies, and till nowadays significant progresses have been made in the inorganic and organic chemistry concerning the synthesis, characterization, and application of this large group of metal complexes. Concerning their structure, complexes were considered those compounds which do not fit within the classical theory of valence, meaning that the combination ratio of the elements exceeded their valences. This coordination theory elaborated by Alfred Werner indicated that the secondary valences of the elements are involved in the formation of the second-order combinations leading to the actual representation of the complexes formed by the first coordination sphere marked between brackets [central atom (ligand)] and the second coordination sphere (ionization sphere) coming outside of the brackets. The central atom can be any chemical element; meanwhile, the ligands can be ions, atoms, or neutral molecules, which can act as donors . Neutral molecules or mono-/polyatomic anions which have one or more unshared electron pairs can act as mono-/polydentate ligands, the latter ones form complexes with cyclic structure known as chelates. A large number of pharmaceutical substances behave in vivo or in vitro conditions as ligands and chelating agents .
The number and the large structural variety of these complexes could not allow a rigorous systematization, even though some attempts by using certain classification criteria have been made such as the number of the central atoms, the charge of the complex ion, the type of ligands, and the coordination number. The coordination compounds were classified into Werner complexes, complexes with metal-metal bonds, metal carbonyls, clusters, complexes with macrocyclic ligands, molecular complexes (adducts, clathrates), chelates, and metal-organic complexes .
Natural metal complexes consisting of a central metal atom or ion (especially of the 3D transition metals) are involved in a plenty of biological mechanisms among which photosynthesis, transport of oxygen in blood, coordination of some metabolic processes, pathological states, enzymatic reactions, etc., even though the metallic ions represent only 3% of the body composition. Many biomolecules (amino acids, peptides, carboxylic acids, etc.) can form metal complexes with different stabilities having biomedical importance. Some drugs have a certain therapeutic effect (e.g., antimicrobial, diuretic, antidepressant) due to the complexation of the metallic ion (Cu2+, Zn2+, Fe2+, Mg2+, etc.) essential for a certain biochemical process. Metal complexes and products containing oligoelements are widely used in therapy due to their pharmacodynamic properties, bioavailability enhancement, and toxicity decrease of some metal ions .
The main aspects concerning the formation of complexes between pharmaceutical substances and various ligands are supported by several observations. According to the biological, physiological, and pathophysiological role of metal ions and ligands with pharmacological effect, metal ions present a great importance in carrying out the vital functions of living organisms acting as complexes or chelates and also in the analysis and control methods of drug substances by forming complexes that can be detected by spectral techniques. The use of ligands, chelating agents, or complexes in medicine and biology concerns several purposes such as antidotes in poisoning with metal ions or hydrocyanic acid or cyanides; introduction in the living organisms of some essential metal ions found to be deficient; depriving bacteria, viruses, or microbial enzyme systems of micronutrients essential for their work; or providing toxic metals for the pathogenic agents .
Many coordination complexes have been used in medicine containing metals such as platinum (cisplatin as anticancer chemotherapy drug), gold (as auranofin used for rheumatoid arthritis), technetium and rhenium (as radiopharmaceuticals used in imaging and radiotherapy), ruthenium (as anticancer drug), gadolinium, cobalt, lithium, bismuth, iron, calcium, lanthanum, gallium, tin, arsenic, rhodium, copper, zinc, aluminum, lutetium, vanadium, manganese, etc. [3, 4]. Only a reduced number of Co(III) complexes can be mentioned as having biochemical properties: vitamin B12, a natural organometallic complex of Co(III) with glyoxime. Other important examples are the series of Co(III) complexes containing N- and O-donor ligands based on a chelating Schiff base (imidazole, methylimidazole) with efficiency in the treatment of epithelial herpetic keratitis (the molecular target is supposed to be a virus protease containing histidine), adenovirus keratoconjunctivitis, and human immunodeficiency virus type 1. [Co(NH3)6]Cl3 presents potent antiviral activity (against Sindbis virus). Some studies reported also the antibacterial activity of Co(II) and Co(III) complexes against
It was demonstrated that the antibacterial activity was increased upon chelation making the ligand a more powerful agent [5, 6]. The complexation of derivatives of sterically hindered
Metal complexes have become an emerging tool in drug discovery being widely used as therapeutic compounds to treat several human diseases such as carcinomas, lymphomas, infection control, diabetes, anti-inflammatory, and neurological disorders [8, 9]. Due to various implications and applications of complexes (especially the chelates) in the biomedical field, many aspects are required to be studied such as their nature, their stability, the factors determining their formation and stability, and possibilities for preventing some reactions and for releasing a metal ion from a complex; all these are necessary in order to understand how they act in biological processes .
2. Physicochemical characterization of metal complexes of some pharmaceuticals
The coordination complexes of a wide range of pharmaceutical substances [pyrazinamide (PZA), nicotinamide (NAM), nicotinic acid (NIC), tolbutamide (TBA), theophylline (TEO), captopril (CFL), clonidine (CLN), and guanfacine (GUAF)] with transition metals [Cu(II), Cd(II), Ni(II), Mn(II), Zn(II), and Co(II)] were synthesized and then characterized by using various techniques such as elemental analysis, spectral, electrochemical, thermal, and microscopic methods.
2.1. Metal complexes of pyrazinamide
Pyrazinamide (PZA) (pyrazine carboxamide) is a nicotinamide analogue used as a first-line drug to treat tuberculosis. The complexes of PZA with Cu(II) were assessed by different techniques such as elemental analysis, spectral methods [Fourier transform infrared spectroscopy (FTIR), FT-Raman spectrometry, mass spectrometry], and scanning electron microscopy (SEM) coupled with X-ray spectroscopy [energy-dispersive spectroscopy (EDS)] [1, 10–13].
The elemental analysis indicated that the combination ratio of metal:ligand (Me:L) is 1:2 for [Cu(PZA)2]Cl2 and [Cu(PZA)2](C6H5COO)2 complexes. The mass spectra of the complex of PZA with Co(II) benzoate revealed the identity and the purity of PZA and of the complex fragments confirming its structure (Figure 1) [1, 10].
The FTIR spectra of the complexes highlighted that –C═O groups and nitrogen from the pyrazine ring are implied in the coordination process (Table 1) . Comparing the Raman spectra of PZA and of [Cu(PZA)2]Cl2, another analytical evidence for the complex formation is obtained. The appearance of new band characteristic for the Me:L bonds can be observed analyzing in detail the spectral region of low values of wave number (Figure 2) [1, 11, 12].
The morphology and the crystal structure of the two complexes were revealed by the SEM images and EDS spectra (Figures 3 and 4). The first complex, [Cu(PZA)2](C6H5COO)2, presented irregular conglomeration with different shapes and dimensions (Figure 3A); meanwhile, the second one, Cu(PZA)2]Cl2, presented acicular and elongated particles with an average size of about 1.5 microns (Figure 4A) [1, 14].
2.2. Metal complexes of nicotinamide
Nicotinamide (NAM) (3-pyridine carboxylic acid amide) is the amide of nicotinic acid playing an important role in the biosynthesis of pyridine nucleotides, and it is a reactive moiety of the coenzyme nicotinamide adenine dinucleotide, a soluble electron carrier in biochemical reactions. The NAM complexes with transition metals [Cu(II), Cd(II), Hg(II)] were synthesized and characterized by using elemental analysis, UV-Vis, and FTIR spectroscopy [1, 15, 16]. The spectral data confirmed tetradentate coordination of NAM with Hg(II), Cd(II), and hexadentate coordination with Cu(II). In the FTIR spectra of these complexes, it can be observed that the characteristic bands of NAM are slightly shifted after coordination (Table 2) . The slight shifting of the bands from NAM complexes with Hg may be explained by the stereochemistry of HgCl2, which is less bulky than Cu(C6H5COO)2 and Cd(SCN)2.
2.3. Metal complexes of nicotinic acid
Nicotinic acid (NIC) (pyridine-3-carboxylic acid) known as vitamin B3, niacin, has two important pharmacological properties: peripheral vasodilator and hypocholesterolemic drug. Its complexes with Co(II) and Cu(II) were synthesized and characterized by elemental analysis and spectral methods [FTIR spectroscopy, Raman spectroscopy, and surface-enhanced Raman spectroscopy (SERS)] (Figure 5). The significant differences observed from the spectral data of the metal complexes can be attributed to the coordination process with the metal ions: the stretching vibrations ν(C─C) from the pyridine ring (1500–1600 cm−1) and
|Assignment (cm−1)||NIC Raman (cm−1)||NIC SERS (cm−1)||Cu(NIC)2 (CH3COO)2 Raman (cm−1)||Cu(NIC)2 (CH3COO)2 SERS (cm−1)||Co(NIC)2 (CH3COO)2 Raman (cm−1)||Co(NIC)2 (CH3COO)2 SERS (cm−1)|
2.4. Metal complexes of guanfacine
Guanfacine (GUAF) (
2.5. Metal complexes of theophylline
Theophylline (TEO) (3,7-dihydro-1,3-dimethyl,1H-purine-2,6-dione) also known as 1,3-dimethyl-xanthine belongs to the class of peripheral and cerebral vasodilator drugs. Metal complexes of TEO were synthesized having the general formula: [Men(TEO)x]Am ⋅ yH2O, where Me = Cu(II), Co(II), Cd(II), Zn(II), and Ni(II) and A = CH3COO−, C6H5COO−; n = 1, x = 1 or 2, m = 2, and y = 2 or 4. The combination ratio was determined by using elemental analysis and conductometric titration; meanwhile, the number of water molecules was determined by using thermal analysis [2, 19–22].
The combination ratio Me:TEO is 1:2 for the complexes having the acetate anion. The complex [Cu(TEO)2](CH3COO)2 has a high thermal instability even at 40°C, its thermal decomposition being already started. On the thermal curves, eight stages of decomposition, all scarcely separable, can be observed. The first five were weakly endothermic, and three were strongly exothermic. The X-ray diffractogram revealed that this complex crystallizes in the monoclinic system. The microscopic analysis showed a mixture of particles with different shapes: acicular, flake, irregular, and lamellar (Figure 7) [2, 19–22].
In the case of [Cd(TEO)2](CH3COO)2, the last stage of thermal decomposition was not achieved in the investigated temperature range; therefore, heating was required up to a higher temperature (850°C) when constant weight was reached corresponding to the cadmium oxide. The complex crystallizes in the monoclinic system, and it presents microcrystals with parallelepiped shape (Figure 8) [2, 19, 21, 22].
The thermal decomposition of [Co(TEO)2](CH3COO)2 takes place in four stages: one endothermic and three exothermic. It presents monoclinic crystal system, and the microcrystals have a tabular form (Figure 9). The complex [Zn(TEO)2](CH3COO)2 presented similar properties as [Cd(TEO)2](CH3COO)2 complex [2, 19, 21, 22].
The endothermic peak at 272°C, which is characteristic for TEO decomposition, is not found in the differential scanning calorimetry (DSC) curves of the complexes, being a credible argument for the complex synthesis and not as a simple mechanical mixture (Figure 10) [2, 19].
The FTIR data also indicated the complex formation: the disappearance of the symmetric vibration band of ─C═O from TEO at 1717 cm−1 in the complexes spectra indicating that this bond is involved in the formation of Me:TEO coordinative bond; the deformation vibration of Me:N bond found at 570–685 cm−1, the appearance of symmetric and asymmetric stretching vibrations of the ─COOH group (1260–1250 and 1535–1530 cm−1), and the possibility of coordinating also the water of crystallization (appearance of large bands at 3050–3500 cm−1) (Figure 11) [2, 19, 21, 22].
The combination ratio Me:TEO is 1:1 for the complexes having the benzoate anion: [Co(TEO)](C6H5COO)2·2H2O, [Ni(TEO)](C6H5COO)2·2H2O, and [Cu(TEO)](C6H5COO)2·2H2O. Their thermal decomposition takes place in four stages, the first one being the stage of loss of water of crystallization (Figure 12A). The FTIR data are similar with those of the complexes mentioned above (having the acetate group as anion); in addition, the specific vibration band of the aromatic ring (1438, 1442, 1440 cm−1) appears. The microscopic image of [Co(TEO)](C6H5COO)2 showed the acicular shape of the particles (Figure 12B) [2, 20].
2.6. Metal complexes of captopril
The chemical structure of captopril (CPL), a dipeptide derivative of
|The molecular formula and weight||Color||Melting point (°C)||C%|
|[Cd(CPL)2][HgI4] M = 1255.18||White||210||17.09/17.21||2.56/2.39||1.881/2.23||5.579/5.099|
|[Zn(CPL)2][HgI4] M = 1244.18||White||165||16.94/17.8||3.019/2.48||1.866/2.31||5.547/5.29|
|[Ni(CPL)2][HgI4] M = 1199.48||Greenish yellow||170||18.07/18.01||3.022/2.5||1.955/2.33||6.083/5.33|
|[Co(CPL)2][HgI4] M = 1199.68||Light pink||180||17.84/18.01||2.866/2.51||1.938/2.31||6.148/5.43|
|[Mn(CPL)2][HgI4] M = 1195.68||White crystals||182||18.04/18.06||2.648/2.50||1.946/2.34||5.85/5.35|
CPL forms complexes with transition metals mentioned above in the presence of tetraiodomercurate anion, [HgI4]2−. The formation and the structure of these complexes are observed in the data of the elemental analysis and in the UV and IR spectra of the complexes with changes of the wavelength values and of absorbance due to the presence of Me:CPL bonds. In the IR spectra of the complexes, a diminution of the band at 1748 cm−1 of ─C═O from the carboxyl group, in comparison with the IR spectrum of CPL, was observed. A wider band appeared at 1600 cm−1 due to the overlapping of the bands corresponding to ─C═O from the amide group. In addition, a new band is observed at 1450 cm−1 due to ─C═O from the carboxyl group (─COO−). In the IR spectra of the Zn:CPL complex, the band corresponding to ─C═O from carboxyl group decreased. It is possible that the reaction with some metals was not completely performed or some degradation products of CPL may be involved in the complexation reaction. In the case of the complex Cu2IICPL2(H2O)2, the IR spectra have indicated the participation of ─COOH, ─C═O, and ─SH groups in coordination along with H2O included in the inner coordination sphere [23, 24].
|Complex||λ (nm)||A%1 cm||Concentration (μg %)|
2.7. Metal complexes of tolbutamide
Tolbutamide (TBA) (
2.8. Metal complexes of clonidine
Clonidine (CLN) (2[(2,6-dichlorophenyl)imino]-imidazolidine) is a centrally acting α2 adrenergic agonist used as antihypertensive drug. Metal complexes of CLN such as [Me(CLN)2][HgI4] where Me = Cd(II), Mn(II), Ni(II), and Cu(II) were synthesized and studied by elemental analysis, FTIR spectroscopy, Raman spectroscopy (Figure 13), and EPR spectroscopy confirming the structure and the changes in the complex conformation .
3. Biomedical significance of metal complexes with pharmaceuticals
The study of the complexes structure and of their biological importance represented the major research interest toward the use of organic drugs as ligands in coordination chemistry for their application in the biomedical field.
The molecules of the pharmaceutical substances have one or more unshared electron pairs that can function as ligands. In fact, many of the basic components of living organisms (amino acids, peptides, proteins, hormones, lipids, carbohydrates, etc.) may function as ligands because they contain donor atoms in their molecules such as nitrogen, oxygen, sulfur, and phosphorus. It is well known that many molecules of drug substances act as ligands both in vitro and in vivo conditions. It is noteworthy to mention that in vivo these ligands will compete for a particular metal ion with a variety of other ligands determining that the extrapolation of this in vitro behavior should be done with moderation. It should always be taken into consideration that the therapeutic effect will be mainly influenced by the conformation of the drug ligands molecules and by their ability to combine with receptors.
Thus, the use of these metal complexes in the biomedical field can be realized by various purposes such as the introduction in the body of deficient metal ions, the use of the ligands as antidotes in various intoxications with metals, and the acquirement of pharmacotherapy effects by blocking metal ions essential for some enzymatic systems. Metal ions are of great importance not only in the vital functions of living organisms, but also they can be intensively used in analysis and control methods for pharmaceutical substances by forming complexes that can be detected by using different physicochemical methods such as spectroscopy, chromatography, microscopy, etc.
Transition metal complexes find their application in catalysis, material synthesis, photochemistry, therapy, and diagnostics. Various chemical, optical, and magnetic properties of the metal complexes of some pharmaceutical substances (pyrazinamide, nicotinamide, nicotinic acid, tolbutamide, theophylline, captopril, clonidine, and guanfacine) have been studied by using a wide range of techniques. The spectral methods such as Fourier transform infrared spectroscopy, Raman spectroscopy, surface-enhanced Raman spectroscopy, X-ray spectroscopy, mass spectrometry, ultraviolet
Jurca T Combinatii complexe ale metalelor tranzitionale cu substante medicamentoase. Oradea: Editura Universitatii din Oradea; 2008. 205 p. ISBN: 978-973-759-585-0.
Marian E, Complecsi ai unor metale tranzitionale cu substante medicamentoase. Timişoara: Editura Politehnica; 2009. 189 p. ISBN: 978-973-625-876-3.
Chang EL, Simmers C, Knight DA. Cobalt complexes as antiviral and antibacterial agents. Pharmaceuticals. 2010;3:1711–1728. DOI: 10.3390/ph3061711
Nagy L, Csintalan G, Kalman E, Sipos P, Szventnik A. Applications of metal ions and their complexes in medicine I. Acta Pharmaceutica Hungarica. 2003;73(4):221–236.
Warra AA, Transition metal complexes and their application in drugs and cosmetics – A review. Journal of Chemical and Pharmaceutical Research. 2011;3(4):951–958.
Storr T, Thompson KH, Orvig C. Design of targeting ligands in medicinal inorganic chemistry. Chemical Society Review. 2006;35(6):534–544.
Loginova NV, Kovalchuk TV, Polozov GI, Osipovich, NP, Chernyavskaya AA, Sorokin VL, Shadyro OI. Redox-active antimicrobial metal complexes with sterically hindered o-diphenol and o-aminophenol derivatives. In: Blanc G, Moreau D, editors. Biometals: Molecular Structures, Binding Properties. Hauppauge ed. New York: Nova Science Publisher; 2010. pp. 59–90.
Pattan SR, Pawar SB, Vetal SS, Gharate UD, Bhawar SB. The scope of metal complexes in drug design - a review. Indian Drugs. 2012;49(11):5–12.
Chiang L, Jones MR, Ferreira CL, Storr T. Multifunctional ligands in medicinal inorganic chemistry–current trends and future directions. Current Topics in Medicinal Chemistry. 2012;12(3):122–144.
Jurca T, Bănică F, Bungău S. Studiul spectrelor de masă ale pirazinamidei şi combinaţiilor sale complexe cu benzoatul de cupru (II). Revista de Chimie. 2006;57(8):859–861.
Jurca T, Banica F, Cavalu S, Simon V, Cinta Panzaru S. FT-IR and Raman studies of pyrazinamide and its complex combination with Cu(II). Studia Universitatis Babes-Bolyai Physica. 2004;69(3):63–67.
Jurca T, Cavalu S, Canta Pinzaru S, Simon V. Vibrational and EPR analysis of new complexes of pyrazinamide with Cu(II). Studia Universitatis Babes-Bolyai. 2003;68(2):457–460.
Simon V, Jurca T, Simon S. Transition metal effect on the structure of pyrazinamide complexes. International Journal of Modern Physics B. 2004;18:1–8.
Jurca T, Marian E. Scanning electronic microscopy study of new pyrazinamide compounds with metallic ions. Farmacia. 2009;57(2):247–254.
Cavalu S, Jurca T, Damian G. Synthesis and spectroscopic studies of metallic nicotinamide complexes. Farmacia. 2003;51(3):92–99.
Jurca T, Cavalu S, Vicaş L, Damian G, Bănică F. ATR FT-IR studies of transitional nicotinamide metallic complexes. Revista de Chimie. 2004;55(7):492–494.
Jurca T, Marian E, Cavalu S. Raman and SERS investigation of new synthesized nicotinic acid metallic complexes. Revista de Chimie. 2009;60(3):320–322.
Jurca T, Marian E, Banica F. Interaction of metal ions with guanfacine. Revista de Chimie. 2010;61(5):487–490.
Marian E, Jurca T, Kacso I, Borodi G, Bratu I, Structure investigations of some complexes of theophylline with transitional metals. Revista de Chimie. 2009;60(6):599–604.
Marian E, Jurca T, Banica F, Tita B, Tita D, Scanning electronic microscopy study of new theophyline compounds with metallic ions. Revista de Chimie. 2008;59(5):495–498.
Marian E, Jurca T, Banica F, Morgovan C, Bratu I. Thermal analysis and Raman spectrometry of some complexes of theophylline with transitional metals. Revista de Chimie. 2010;61(6):569–574.
Marian E, Cavalu S, Jurca T, Banica F, Bratu I. Synthesis, spectroscopic behavior and scanning electron microscopy of new complexes of theophylline with some transitional metals ions. Farmacia. 2010;58(6):749–757.
Vicaş LG, Inhibitorii enzimei de conversie: Date analitice şi farmacologice. Oradea: Editura Universităţii din Oradea; 2006. 126 p. ISBN: 973-613-808-9.
Jurca T, Vicaş L, Complexes of the ACE – Inhibitor captopril. Farmacia. 2010;58(2):198–202.
Marian E, Jurca T, Banica F, Vicas L. Sinteza si caracterizarea fizico-chimica a combinatiilor complexe ale tolbutamidei cu ionii de cupru (II). Revista de Medicină şi Farmacie Târgu-Mureş. 2004;50(2):171–175.
Marian E, Jurca T, Simon V, Banica F, Cavalu S. Spectroscopic behaviour of copper complexes of tolbutamine. Studia Universitatis Babes-Bolyai Physica. 2004;69(2):71–75.
Marian E, Jurca T, Simon V, Vicas L, Bănică F, IR and EPR investigation of copper complexes of tolbutamide. Timişoara Medical Journal. 2005;55(5):130–132.
Jurca T, Cavalu S, Cinta-Panzaru S, Simon V. Synthesis and spectroscopic characterisation of guanfacine with transition metals. In: The 10th European Conference on the Spectroscopy of Biological Molecules; 30.08–4.09; Szeged, Hungary; 2003. Book of Abstracts, p. 116. ISBN: 963-482-614-8.